Research led by Roswell Park Comprehensive Cancer Center and Genome Protection Inc. has detected activity in the “dark genome” that could help transform the diagnosis and treatment of five of the 10 most deadly cancers in the U.S.

Roswell Park Comprehensive Cancer Center and Generate:Biomedicines announce a strategic collaboration to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors. In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.

The Commission on Cancer (CoC), a quality program of the American College of Surgeons, has fully reaccredited Roswell Park Comprehensive Cancer Center for three years. The Commission on Cancer gives recognition to cancer centers that provide multidisciplinary, patient-centered cancer care. Roswell Park is one of the longest-standing CoC programs, having maintained accreditation from the organization continuously since 1931.

A program designed to help African Americans make informed decisions about prostate cancer early detection and treatment will expand in Erie County thanks to a New York State Department of Health (DOH) grant to Adam Sumlin, PhD, MBA, Assistant Professor of Oncology at Roswell Park Comprehensive Cancer Center. The grant — one of only four awarded in the state — provides $650,000 over the next five years through the DOH program Peer Education, Outreach & Shared Decision-Making for Persons at High Risk of Prostate Cancer.